CA3248186A1 - GPR120 AGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE - Google Patents

GPR120 AGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

Info

Publication number
CA3248186A1
CA3248186A1 CA3248186A CA3248186A CA3248186A1 CA 3248186 A1 CA3248186 A1 CA 3248186A1 CA 3248186 A CA3248186 A CA 3248186A CA 3248186 A CA3248186 A CA 3248186A CA 3248186 A1 CA3248186 A1 CA 3248186A1
Authority
CA
Canada
Prior art keywords
phenyl
gpr120
sulfamoyl
heptanoic acid
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3248186A
Other languages
English (en)
French (fr)
Inventor
Marcello Allegretti
Andrea Aramini
Gianluca Bianchini
Silvia D'ALESSIO
Rafael CYPRIANO DUTRA
Original Assignee
Dompe Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Farmaceutici SpA filed Critical Dompe Farmaceutici SpA
Publication of CA3248186A1 publication Critical patent/CA3248186A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3248186A 2022-03-03 2023-03-03 GPR120 AGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE Pending CA3248186A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22160079.4 2022-03-03
EP22160079.4A EP4238557A1 (en) 2022-03-03 2022-03-03 Gpr120 agonists for the treatment of inflammatory bowel disease
PCT/EP2023/055490 WO2023166203A1 (en) 2022-03-03 2023-03-03 Gpr120 agonists for the treatment of inflammatory bowel disease

Publications (1)

Publication Number Publication Date
CA3248186A1 true CA3248186A1 (en) 2023-09-07

Family

ID=80628869

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3248186A Pending CA3248186A1 (en) 2022-03-03 2023-03-03 GPR120 AGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

Country Status (7)

Country Link
US (1) US20250177329A1 (cg-RX-API-DMAC7.html)
EP (2) EP4238557A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025507962A (cg-RX-API-DMAC7.html)
CN (1) CN119031908A (cg-RX-API-DMAC7.html)
CA (1) CA3248186A1 (cg-RX-API-DMAC7.html)
IL (1) IL314689A (cg-RX-API-DMAC7.html)
WO (1) WO2023166203A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120919101A (zh) * 2025-09-26 2025-11-11 南京农业大学 Gw9508在制备治疗轮状病毒的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3281937A1 (en) * 2016-08-09 2018-02-14 Dompé farmaceutici S.p.A. Sulfonamides as gpr40- and gpr120-agonists
CN111317728A (zh) * 2018-12-14 2020-06-23 中国科学院大连化学物理研究所 天然来源ffa4(gpr120)受体激动剂及其应用

Also Published As

Publication number Publication date
EP4486327A1 (en) 2025-01-08
EP4238557A1 (en) 2023-09-06
WO2023166203A1 (en) 2023-09-07
CN119031908A (zh) 2024-11-26
US20250177329A1 (en) 2025-06-05
JP2025507962A (ja) 2025-03-21
IL314689A (en) 2024-10-01

Similar Documents

Publication Publication Date Title
AU2005271878B2 (en) Compositions for delivering peptide YY and PYY agonists
WO2015147240A1 (ja) 敗血症の予防治療剤
JP3667381B2 (ja) 解熱鎮痛剤
EP2059234B1 (en) Method for reducing or alleviating inflammation in the digestive tract
CN101674823A (zh) 用于与增强的5-脂氧合酶和/或白三烯活性有关的疾病(例如哮喘)的r-齐留通
KR20210100594A (ko) 염증성 장애의 치료에 사용하기 위한 벤조이미다졸 유도체
US20250177329A1 (en) Gpr120 agonists for the treatment of inflammatory bowel disease
JP5567484B2 (ja) 機能性消化管障害の予防及び/又は治療剤
JP5575927B2 (ja) ペントキシフィリンの便秘の予防または治療における応用
AU2020386913A1 (en) Methods for treating inflammatory bowel disease
US11648240B2 (en) Pharmaceutical composition comprising famotidine, lidocaine and melatonin
RU2829636C1 (ru) Фармацевтическая композиция на основе 5-пентилрезорцинола для лечения воспалительных заболеваний кишечника
WO2022051319A1 (en) Fixed dose combinations of chs-131 and a dpp-4 inhibitor
WO2021230264A1 (ja) 胆道系疾患の診断補助・予防・治療剤
US10471005B2 (en) Low dose pharmaceutical composition
CN119405649A (zh) 呋喃二烯酮在制备治疗炎症性肠病药物中的应用
JP5410816B2 (ja) 小腸粘膜障害の予防・治療薬剤としての医薬組成物
IT201900019858A1 (it) Composizione farmaceutica comprendente una combinazione sinergica di ibuprofene e N-acetilcisteina
JP2009126813A (ja) 口腔粘膜疾患の治療剤
WO2026008018A1 (zh) 一类肝靶向的蛋白降解剂偶联物及其用途
EA045566B1 (ru) Новые ингибиторы глутаминилциклаз и их применение для лечения различных заболеваний
CZ20022630A3 (cs) Pouľití rofleponidu pro léčení syndromu dráľdivého střeva

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240809

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20241016

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250115

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250115

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250115

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20250210

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250214